Reviewing BioCryst Pharmaceuticals (BCRX) and The Competition
BioCryst Pharmaceuticals (NASDAQ: BCRX) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare BioCryst Pharmaceuticals to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, valuation, profitability and earnings.
Risk and Volatility
BioCryst Pharmaceuticals has a beta of 3.07, meaning that its share price is 207% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals’ rivals have a beta of 8.05, meaning that their average share price is 705% more volatile than the S&P 500.
84.7% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.6% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares BioCryst Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BioCryst Pharmaceuticals Competitors||-5,310.39%||-218.43%||-39.49%|
This is a summary of recent recommendations and price targets for BioCryst Pharmaceuticals and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BioCryst Pharmaceuticals Competitors||873||3235||11723||233||2.70|
BioCryst Pharmaceuticals currently has a consensus price target of $9.14, suggesting a potential upside of 81.41%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.85%. Given BioCryst Pharmaceuticals’ higher probable upside, research analysts clearly believe BioCryst Pharmaceuticals is more favorable than its rivals.
Valuation & Earnings
This table compares BioCryst Pharmaceuticals and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|BioCryst Pharmaceuticals||$26.35 million||-$55.14 million||-7.88|
|BioCryst Pharmaceuticals Competitors||$284.49 million||$34.10 million||73.95|
BioCryst Pharmaceuticals’ rivals have higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
BioCryst Pharmaceuticals rivals beat BioCryst Pharmaceuticals on 7 of the 12 factors compared.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.